Status:
COMPLETED
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). The study...
Eligibility Criteria
Inclusion
- Surgically or medically castrated
- Bone metastasis
- Rising PSA
Exclusion
- Opiate use
- Prior chemotherapy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
447 Patients enrolled
Trial Details
Trial ID
NCT00090363
Start Date
July 1 2004
End Date
August 1 2011
Last Update
January 8 2013
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tucson, Arizona, United States
2
Research Site
Los Angeles, California, United States
3
Research Site
Gainsville, Florida, United States
4
Research Site
Chicago, Illinois, United States